User profiles for A.A. Schnitzbauer

Andreas Schnitzbauer

Universitätsklinikum Frankfurt, Goethe Universität Frankfurt am Main
Verified email at kgu.de
Cited by 13162

Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services

…, J Hallet, JB Matthews, AA Schnitzbauer… - Journal of British …, 2020 - academic.oup.com
Background The ongoing pandemic is having a collateral health effect on delivery of surgical
care to millions of patients. Very little is known about pandemic management and effects on …

Systematic review and meta-analysis of feasibility, safety, and efficacy of a novel procedure: associating liver partition and portal vein ligation for staged hepatectomy

E Schadde, AA Schnitzbauer, C Tschuor… - Annals of surgical …, 2015 - Springer
Background Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)
is a novel strategy to resect liver tumors despite the small size of the liver remnant. It is an …

Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for …

AA Schnitzbauer, SA Lang, H Goessmann… - Annals of …, 2012 - journals.lww.com
Objective: To evaluate a new 2-step technique for obtaining adequate but short-term
parenchymal hypertrophy in oncologic patients requiring extended right hepatic resection with …

Early survival and safety of ALPPS: first report of the International ALPPS Registry

…, O Soubrane, AA Schnitzbauer… - Annals of …, 2014 - journals.lww.com
… As you know, the ratio of body weight was the methodology used by Schnitzbauer in the
initial ALPPS report. This ratio to body weight is more accurate, especially in very low volumes. …

Calcineurin inhibitor minimization protocols in liver transplantation

SA Farkas, AA Schnitzbauer, G Kirchner… - Transplant …, 2009 - Wiley Online Library
Liver transplant recipients are at increasingly high risk for suffering from impaired renal
function and probable need of renal replacement therapy. Extended criteria organs and …

[HTML][HTML] Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial

EK Geissler, AA Schnitzbauer, C Zülke… - …, 2016 - journals.lww.com
Background We investigated whether sirolimus-based immunosuppression improves outcomes
in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC). Methods …

Prediction of mortality after ALPPS stage-1: an analysis of 320 patients from the international ALPPS registry

E Schadde, DA Raptis, AA Schnitzbauer… - Annals of …, 2015 - journals.lww.com
Objectives: The aim of this study was to identify predictors of 90-day mortality after Associating
Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS), available after …

[HTML][HTML] A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver …

AA Schnitzbauer, C Zuelke, C Graeb, J Rochon… - BMC cancer, 2010 - Springer
Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR)
inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) …

mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors

AA Schnitzbauer, N Filmann, R Adam… - Annals of …, 2020 - journals.lww.com
Objective: The aim of this study was to evaluate the survival benefit of sirolimus in patients
undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC)(exploratory analysis …

Mortality after liver surgery in Germany

…, WO Bechstein, AA Schnitzbauer - Journal of British …, 2019 - academic.oup.com
Background Mortality rates after liver surgery are not well documented in Germany. More
than 1000 hospitals offer liver resection, but there is no central regulation of infrastructure …